Publications by authors named "Aprajita Mattoo"
Background And Hypothesis: Hepatitis C virus (HCV) positive-to-negative kidney transplants (KT) require direct acting antiviral therapy, but the optimal timing and duration remain unclear. We hypothesized that 14-day prophylactic course of glecaprevir/pibrentasvir 300/120 mg (GLE/PIB) would be safe and effective at treating donor-derived HCV viremia.
Methods: This was a prospective, single-center, single-arm, open-label pilot study.
Article Synopsis
- Optimizing organ transplant success involves more than just matching Human Leukocyte Antigen (HLA) types; it requires a deeper understanding of both classical and non-classical HLA genes to improve long-term graft survival.
- High-resolution HLA genotyping and advanced tools like eplet mismatch calculators and the PIRCHE-II algorithm can provide better predictions of organ rejection compared to traditional methods.
- While full-scale use of molecular matching in deceased donor organ allocation is not yet feasible, its application in living donations and outpatient management shows promise for improving transplant outcomes.
Objectives: We designed this study to test whether clazakizumab, a direct interleukin-6 inhibitor, benefits patients hospitalized with severe or critical COVID-19 disease accompanied by hyperinflammation.
Design: Multicenter, randomized, double-blinded, placebo-controlled, seamless phase II/III trial.
Setting: Five U.
Despite utilization of hepatitis C viremic organs for hepatitis C naïve recipients (HCV D+/R-) in other solid organ transplants, HCV viremic pancreata remain an unexplored source of donor organs. This study reports the first series of HCV D+/R- pancreas transplants. HCV D+/R- had shorter waitlist times compared to HCV D-/R-, waiting a mean of 16 days from listing for HCV-positive organs.
View Article and Find Full Text PDFBACKGROUND Patients receiving immunosuppressive therapies might be more susceptible to COVID-19. Conversely, an exaggerated inflammatory response to the SARS-CoV-2 infection might be blunted by certain forms of immunosuppression, which could be protective. Indeed, there are data from animal models demonstrating that complement may be a part of the pathophysiology of coronavirus infections.
View Article and Find Full Text PDF